CIT No. 25-00187: Solvay Files Defense Brief Against Jiangxi Brother Pharma Rule 56.2 Motion
Solvay USA, LLC filed a 51-page response brief opposing Jiangxi Brother Pharmaceutical Co., Ltd.'s Rule 56.2 Motion for Judgment on the Agency Record in CIT Case No. 25-00187. A reply is due by July 24, 2026, with Solvay acting as defendant-intervenor supporting the U.S. government's trade agency determination.
What changed
CourtListener posted a court record: Solvay USA, LLC filed a 51-page response brief opposing Jiangxi Brother Pharmaceutical Co., Ltd.'s Rule 56.2 Motion for Judgment on the Agency Record in CIT Case No. 25-00187. A reply is due by July 24, 2026, with Solvay acting as defendant-intervenor supporting the U.S. government's trade agency determination.
Procedural posture
The record belongs to docket 1:25-cv-00187; the source should be read for motion, order, judgment, briefing posture, and deadlines, not for unsupported merits conclusions.
Affected scope
HS scope: 29; countries: US, CN; instruments: AD/CVD
Practical impact
Use this as a litigation-monitoring signal and avoid changing duty treatment unless an order or mandate directly changes the operative rule.
What to check next
Check the docket for deadlines, stays, remand instructions, appeals, and the underlying agency action under review.
Source limits
- No linked Policy Map node is available; this brief uses the briefing row and raw source metadata only.
- This brief is limited to the cited source record and does not confirm later amendments, litigation, implementation guidance, or current legal status.